The Cancer Center at the University of Texas Health Science Center at San Antonio requests $35,200 in support of the Planning and Evaluation process. The Cancer Center has both an External Advisory Board (EAB) and three Internal Advisory Committees, the Executive Committee (EC) for the day to day management, the Scientific Leadership Committee (SLC) for scientific programs and shared resources development and review and the Internal Advisory Committee for more global issues related to the various Schools and the UTHSCSA in general. The Cancer Center Director and leadership interact very closely with it's EAB through many telephone conferences, sending documents for review on a regular basis by on-site visits by the Chair, Dr. John C. Ruckdeschel, members of the EAB and by an annual visit of the EAB. the EAB reviews and advices Director on all activities of the Cancer Center. Their reviews, evaluations and criticisms have led us to develop much stronger Cancer Center Funds to support the EAB are requested ($25,000). The EC and the SLC work very closely together and with the EAB for Strategic planning and evaluations of the programs and shared resources. The Cancer Center uses center-wide retreats and program retreats to further develop strong and effective programs and shared resources and for future recruitment strategies. We request $10,000 to help with the Cancer Center and program retreats.
The CTRC is in a historic period of transition and re-growth after a period of turnnoil and attrition of key personnel. Planning and evaluation funds are critical to maintain our ability to bring in our EAB, and to compensate them for the visits and for grant reviews. Funds for retreats and other meetings of programs are also to maintain the momentum generated by the merger and by the new leadership. These funds help rebuild and further strengthen programs through appropriate planning and evaluation during a transition period.
|Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20|
|Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970|
|Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40|
|Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232|
|Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor Î² Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185|
|Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014|
|Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82|
|Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289|
|Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190|
|Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10|
Showing the most recent 10 out of 853 publications